1 |
Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997;50:882-7
DOI
ScienceOn
|
2 |
Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2002;2:116-23
|
3 |
Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-75
DOI
ScienceOn
|
4 |
Allard P, Fradet Y, Tetu B, Bernard P. Tumor- associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995;1:1195-202
|
5 |
Lodde M, Mian C, Negri G, et al. Effect of intravesical instillation on performance of uCYT+ test. Urology 2004;63:878-81
DOI
ScienceOn
|
6 |
Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000;46:595-605
|
7 |
Sanchez-Carbayo M, Herrero E, Megias J, et al. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1997;161:1110-5
DOI
ScienceOn
|
8 |
Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol 1998;82:727-32
DOI
ScienceOn
|
9 |
Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47
|
10 |
Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-14
DOI
ScienceOn
|
11 |
Cordon-Cardo C, Reuter VE, Lloyd KO, et al. Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. Cancer Res 1988;48:4113-20
|
12 |
van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001;92:768-75
DOI
ScienceOn
|
13 |
King W, Proffitt J, Morrison L, Piper J, Lane D, Seelig S. The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management. Mol Diag 2000;5:309-19
DOI
|
14 |
Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502
DOI
ScienceOn
|
15 |
Annual Report of Cancer Registry Program in Republic of Korea. Ministry of Health and Welfare, Republic of Korea, 2002
|
16 |
Keesee SK, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996;6:189-214
DOI
|
17 |
Thomas L, Leyh H, Marberger M, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7
|
18 |
Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985;45:2405-14
|
19 |
Papanicolaou GN. Marchall VF. Urine sediment smears: A diagnostic procedure in cancers of the urinary tract. Science 1945;101:519-21
DOI
|
20 |
Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 2000;6: 3585-94
|
21 |
Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 1998;82:349-54
DOI
ScienceOn
|
22 |
van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996;48:357-64
DOI
ScienceOn
|
23 |
Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am 1992;19:629-39
|
24 |
Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003;169:921-4
DOI
ScienceOn
|
25 |
Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002;94:2914-22
DOI
ScienceOn
|
26 |
Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997;158:2098-101
DOI
ScienceOn
|
27 |
Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high- grade bladder cancer. Cancer Res 1997;57:778-83
|
28 |
Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410-7
DOI
ScienceOn
|
29 |
Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004;340:57-65
DOI
ScienceOn
|
30 |
Habuchi T, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994;86:1331-5
DOI
ScienceOn
|
31 |
Mayfield MP, Shah T, Flannigan GM, Hamilton Stewart PA, Bibby MC. Telomerase activity in malignant and benign bladder conditions. Int J Mol Med 1998;1:835-40
|
32 |
Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 1997;4:400-5
|
33 |
Ponsky LE, Sharma S, Pandrangi L, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001;166:75-8
DOI
ScienceOn
|
34 |
Tetu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005;18:83-9
DOI
ScienceOn
|
35 |
McCabe RP, Lamm DL, Haspel MV, et al. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin (ogen) degradation products. Cancer Res 1984;44:5886-93
|
36 |
Dalbagni G, Han W, Zhang ZF, et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997;3:1593-8
|
37 |
Grocela JA, McDougal WS. Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer. Urol Clin North Am 2000;27:47-51
DOI
|
38 |
Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86
DOI
ScienceOn
|
39 |
Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507-19
DOI
ScienceOn
|
40 |
Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161:443-6
DOI
ScienceOn
|
41 |
Katz RL, Sinkre PA, Zhang HH, Kidd L, Johnston D. Clinical significance of negative and equivocal urinary bladder cytology alone and in combination with DNA image analysis and cystoscopy. Cancer Cytopathol 1997;81:354-64
DOI
ScienceOn
|
42 |
Schmetter BS, Habicht KK, Lamm DL, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158:801-5
DOI
ScienceOn
|
43 |
Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1999;345:458-60
DOI
ScienceOn
|
44 |
Sarosdy MF. The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 1997;15:103-6
DOI
ScienceOn
|
45 |
Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997;50:349-53
DOI
ScienceOn
|
46 |
Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;27:53-61
DOI
|
47 |
Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996;271:659-62
DOI
ScienceOn
|